Abstract:OBJECTIVE Contemporary oncological paradigms for adjuvant treatment of low- and intermediate-grade gliomas are often guided by a limited array of parameters, overlooking the dynamic nature of the disease. The authors’ aim was to develop a comprehensive multivariate glioma growth model based on multicentric data, to facilitate more individualized therapeutic strategies. METHODS Random slope models with subject-specific random intercepts were fitted to a retrospective cohort of grade II and III gliomas from the database at Kepler University Hospital (n = 191) to predict future mean tumor diameters. Deep learning–based radiomics was used together with a comprehensive clinical dataset and evaluated on an external prospectively collected validation cohort from University Hospital Zurich (n = 9). Prediction quality was assessed via mean squared prediction error. RESULTS A mean squared prediction error of 0.58 cm for the external validation cohort was achieved, indicating very good prognostic value. The mean ± SD time to adjuvant therapy was 28.7 ± 43.3 months and 16.1 ± 14.6 months for the training and validation cohort, respectively, with a mean of 6.2 ± 5 and 3.6 ± 0.7, respectively, for number of observations. The observed mean tumor diameter per year was 0.38 cm (95% CI 0.25–0.51) for the training cohort, and 1.02 cm (95% CI 0.78–2.82) for the validation cohort. Glioma of the superior frontal gyrus showed a higher rate of tumor growth than insular glioma. Oligodendroglioma showed less pronounced growth, anaplastic astrocytoma—unlike anaplastic oligodendroglioma—was associated with faster tumor growth. Unlike the impact of extent of resection, isocitrate dehydrogenase (IDH) had negligible influence on tumor growth. Inclusion of radiomics variables significantly enhanced the prediction performance of the random slope model used. CONCLUSIONS The authors developed an advanced statistical model to predict tumor volumes both pre- and postoperatively, using comprehensive data prior to the initiation of adjuvant therapy. Using radiomics enhanced the precision of the prediction models. Whereas tumor extent of resection and topology emerged as influential factors in tumor growth, the IDH status did not. This study emphasizes the imperative of advanced computational methods in refining personalized low-grade glioma treatment, advocating a move beyond traditional paradigms.

Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma—Letter

Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma—Response

Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework

Preoperative growth dynamics of untreated glioblastoma: Description of an exponential growth type, correlating factors, and association with postoperative survival

Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma

Quantifying the Growth of Glioblastoma Tumors Using Multimodal MRI Brain Images

A revised mathematical model of pre-diagnostic glioma growth incorporating vascularization and tumor mutational burden

The Prognostic Role of Volumetric MRI Evaluation in the Surgical Treatment of Glioblastoma

Tumor volume features predict survival outcomes for patients diagnosed with diffuse intrinsic pontine glioma

Mathematical modeling of meningioma volume change after radiation treatment

Velocity and pattern of growth of intracranial meningiomas

Exponential Growth of Glioblastoma<i>In Vivo</i>Driven by Rapidly Dividing and Outwardly Migrating Cancer Stem Cells

Diagnosing Progression in Glioblastoma—Tackling a Neuro-Oncology Problem Using Artificial-Intelligence-Derived Volumetric Change over Time on Magnetic Resonance Imaging to Examine Progression-Free Survival in Glioblastoma

Radiotherapy planning for glioblastoma based on a tumor growth model: Improving target volume delineation

Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach

Radt-40. Evaluation Of Smaller Clinical Target Volumes And Patterns Of Progression In Patients With Newly Diagnosed Glioblastoma To Inform Future Directions In Radiation Treatment Planning

Mathematical Modeling of Tumor Growth in Preclinical Mouse Models with Applications in Biomarker Discovery and Drug Mechanism Studies

Prognostic value of 11C-methionine volume-based PET parameters in IDH wild type glioblastoma

From molecular signatures to radiomics: tailoring neurooncological strategies through forecasting of glioma growth

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo